COST-BENEFIT RELATIONSHIP OF THE HUMAN PAPILLOMAVIRUS VACCINE IN CHILE'S NATIONAL IMMUNIZATION PROGRAM.

Authors

DOI:

https://doi.org/10.22370/revmat.1.2024.3869

Keywords:

Cervical cancer, Human Papillomavirus, Human Papillomavirus vaccines

Abstract

Introduction: in 2018, Chile registered a standardised mortality rate of cervical cancer of 6.6 per 100,000 women. Human papillomavirus vaccines represent a new tool for the control of this pathology.

Objective: to determine the cost-benefit ratio of universal vaccination against human papillomavirus in Chile.

Material and methods: the study used an observational correlational study of prospective cohorts, with application of a dynamic model. A cohort of 130,000 girls who underwent the vaccination simulation and a non-vaccinated cohort.

Results: in terms of the cost of benefits, this study showed the following results: a) Girls unvaccinated: US$6,317,408, b) Girls vaccinated: US$3,598,473.

Conclusion: the application of the Human Papillomavirus vaccine is cost-effective for the country's economy.

Downloads

Download data is not yet available.

References

- International Agency for Research in Cancer. Cervical cancer. Disponible en : https://www.iarc.who.int/cancer-type/cervical-cancer/

- Departamento de Estadísticas e Información de Salud. Defunciones y Mortalidad por causas – DEIS [Internet]. Disponible: http://www.deis.cl/?p=2541

- Meisels A, Fortin R. Condylomatous Lesions of the Cervix and Vagina.

Acta cytol. (1976) 505-509.

- McIntyre P. Finding the viral link: the history of Harald zur-Hausen Cancer World, Julio-Agosto, 2005, 32-37.

- World Health Organization. WHO/ Immunization, Vaccines and Biologicals database, as of 31 March 2017. Disponible en: http://www.who.int/entity/immunization/monitoring_surveillance/VaccineIntroStatus.pptx, accessed February 2017.

- World Health Organization. Summary of Key Points from WHO Position Paper, VPH Vaccines, April 9, 2009. https://www.sciencedirect.com/science/article/abs/pii/S0264410X0900721X

- Castillo M, Castillo C. La costo/efectividad potencial de una vacuna contra el VPH en Chile. Boletín de Economía y Salud 2011; 5 : 2-12.

- World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017, N°19, 2017,92,241-268

- Catalá-López F. Efficiency-based healthcare. General concepts on economic evaluation of healthcare interventions. Enferm Clin 2009; 19:35-42.

- Tan-Torres T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.

- Rubio–Terrés C, Echeverría A. Modelos de Markov: Una herramienta útil para el análisis fármaco-económico. Pharmacoeconomics-Spanish Research Articles 2006, Vol 3, Suppl.2:71-7.

- Garzón MO. Carga de la Enfermedad. Rev CES Salud Pública 2012; 3(2): 289-295.

- Valera L, Ramos P, Porte I, Bedregal P. Rechazo de los padres a la vacunación obligatoria en Chile. Desafíos éticos y jurídicos. Rev. chil. pediatr. [Internet]. 2019 Dic [citado 2024 Ene 12]; 90( 6 ): 675-682.Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0370-41062019000600675&lng=es. http://dx.doi.org/10.32641/rchped.v90i6.1002.

- Bolaños-Díaz R, Tejada R, Beltrán J, Escobedo-Palza S. Evaluación costo-efectividad de dos alternativas de vacunación para el virus del papiloma humano en la prevención del cáncer cervical uterino. Rev. perú. med. exp. salud publica [Internet]. 2016 Jul [citado 2024 Ene 12] ; 33( 3 ): 411-418. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342016000300004&lng=es. http://dx.doi.org/10.17843/rpmesp.2016.333.2294.

- Andrés-Gamboa O, Chicaíza L, García-Molina M, Díaz J, González M, Murillo R et al . Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud pública Méx [revista en la Internet]. 2008 Ago [citado 2024 Ene 12] ; 50( 4 ): 276-285. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342008000400005&lng=es.

- Castillo M, Castillo C. La costo/efectividad potencial de una vacuna contra el VPH en Chile. Boletín de Economía y Salud 2011; 5 : 2-12.

- Favato G, Pieri V, Mills R. Analisi costo-efficacia del programma di vaccinazione anti-HPV in Italia: il modello multi-coorte Markov. G. Favato, V. Pieri, R.W. Mills School of Projects, Processes and Systems, Henley Management College, UK; Servizio di Epidemiologia e Farmacia Preventiva (SEFAP), Milano, Supplemento n. 2 alla rivista Farmaci Vol. 31 - n. 2/2007.

- Ministerio de Salud. Estrategia Nacional de Cáncer. Chile 2016. Disponible en : https://www.minsal.cl/wp-content/uploads/2016/10/Estrategia-Nacional-de-Cancer-version-consulta-publica.pdf (Revisado el 12.01.23)

Downloads

Published

2024-05-29

How to Cite

1.
Ibarra Pérez A, Parada Lezcano M, Calvo Irrazabal MN. COST-BENEFIT RELATIONSHIP OF THE HUMAN PAPILLOMAVIRUS VACCINE IN CHILE’S NATIONAL IMMUNIZATION PROGRAM. Mat.Actual [Internet]. 2024 May 29 [cited 2025 Sep. 4];(1):7. Available from: https://margenes.uv.cl/index.php/matroneria/article/view/3869

Issue

No. 1 (2024): Revista Matronería Actual

Section

Artículos

License

Copyright (c) 2024 Revista Matronería Actual

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

__